Overview

All Sanguine study protocols and their resulting samples, which include all Sanguine at-home and apheresis collection programs, are conducted under an Institutional Review Board (IRB). Sanguine operates under an electronic informed consent process which executes 21 CFR part 11 compliant e-signatures, and Sanguine systems interacting with study participant information are HIPAA-compliant.

Sanguine’s fresh whole blood collection ensures high-quality, viable samples for research and therapeutic applications. Available in custom volumes with flexible anticoagulant options, our fresh whole blood is ideal for immunology, hematology, and biomarker research.

Well-characterized whole blood for type 2 diabetes (T2D) research supports studies on insulin resistance, metabolic dysfunction, and therapeutic development for better disease management and prevention.